Galantamine modulates nicotinic receptor and blocks Aβ-enhanced glutamate toxicity
- 17 December 2004
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 325 (3) , 976-982
- https://doi.org/10.1016/j.bbrc.2004.10.132
Abstract
No abstract availableKeywords
Funding Information
- Smoking Research Foundation
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare
This publication has 23 references indexed in Scilit:
- Galantamine Is an Allosterically Potentiating Ligand of Neuronal Nicotinic but Not of Muscarinic Acetylcholine ReceptorsThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Unconventional ligands and modulators of nicotinic receptorsJournal of Neurobiology, 2002
- Dopamine D2‐type agonists protect mesencephalic neurons from glutamate neurotoxicity: Mechanisms of neuroprotective treatment against oxidative stressAnnals of Neurology, 1998
- Interleukin-3-Induced Phosphorylation of BAD Through the Protein Kinase AktScience, 1997
- Nicotinic receptor stimulation protects neurons against β‐amyloid toxicityAnnals of Neurology, 1997
- Introductory Lecture: Allosteric Modulation of Torpedo Nicotinic Acetylcholine Receptor Ion Channel Activity by Noncompetitive AgonistsJournal of Receptors and Signal Transduction, 1997
- Nicotine‐induced Protection Against Glutamate CytotoxicityAnnals of the New York Academy of Sciences, 1996
- Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin NeuropeptidesScience, 1990
- Nicotinic acetylcholine binding sites in Alzheimer's diseaseBrain Research, 1986
- Changes in Nicotinic and Muscarinic Cholinergic Receptors in Alzheimer‐Type DementiaJournal of Neurochemistry, 1986